Renewable Energy Group (NASDAQ:REGI) had its target price upped by research analysts at BWS Financial from $58.00 to $75.00 in a report issued on Monday, The Fly reports. The firm currently has a "buy" rating on the oil and gas company's stock. BWS Financial's price objective points to a potential upside of 59.71% from the stock's current price.
REGI has been the subject of several other research reports. Credit Suisse Group began coverage on shares of Renewable Energy Group in a report on Tuesday, September 1st. They issued an "outperform" rating and a $51.00 price target for the company. Truist began coverage on shares of Renewable Energy Group in a report on Tuesday, September 1st. They issued a "buy" rating and a $70.00 price target for the company. Zacks Investment Research lowered shares of Renewable Energy Group from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. BidaskClub raised shares of Renewable Energy Group from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 19th. Finally, Roth Capital boosted their target price on shares of Renewable Energy Group from $33.00 to $50.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of "Buy" and an average price target of $53.63.
NASDAQ REGI traded up $1.81 during mid-day trading on Monday, reaching $46.96. 959 shares of the stock were exchanged, compared to its average volume of 754,238. Renewable Energy Group has a 1-year low of $13.82 and a 1-year high of $49.32. The business's fifty day simple moving average is $39.91 and its 200 day simple moving average is $28.55. The stock has a market capitalization of $1.77 billion, a PE ratio of 3.66 and a beta of 1.46. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.33 and a current ratio of 2.91.
Renewable Energy Group (NASDAQ:REGI) last issued its earnings results on Tuesday, August 4th. The oil and gas company reported $0.02 EPS for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.36. Renewable Energy Group had a net margin of 21.03% and a return on equity of 12.04%. The business had revenue of $545.96 million for the quarter, compared to the consensus estimate of $502.87 million. On average, analysts anticipate that Renewable Energy Group will post 3.35 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP raised its stake in Renewable Energy Group by 2.0% during the 1st quarter. First Trust Advisors LP now owns 104,698 shares of the oil and gas company's stock valued at $2,299,000 after purchasing an additional 2,098 shares during the last quarter. New York State Common Retirement Fund raised its stake in Renewable Energy Group by 5.7% during the first quarter. New York State Common Retirement Fund now owns 36,000 shares of the oil and gas company's stock valued at $739,000 after buying an additional 1,949 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Renewable Energy Group by 27.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,397 shares of the oil and gas company's stock valued at $70,000 after buying an additional 726 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Renewable Energy Group by 6.5% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 17,710 shares of the oil and gas company's stock valued at $364,000 after buying an additional 1,077 shares during the last quarter. Finally, Swiss National Bank raised its stake in Renewable Energy Group by 1.3% during the first quarter. Swiss National Bank now owns 75,600 shares of the oil and gas company's stock valued at $1,552,000 after buying an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 98.06% of the company's stock.
About Renewable Energy Group
Renewable Energy Group, Inc produces cleaner and lower carbon transportation fuels. The company utilizes an integrated production, distribution, and logistics system to convert natural fats, oils, and greases into advanced biofuels. It operates through Biomass-Based Diesel, Services, and Corporate and Other segments.
Featured Story: What is a support level?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure
Biotech stocks are some of the most volatile for investors to include in their portfolio. And that volatility can be hard to predict. Biotech companies don’t have a firm correlation with the overall economy. And what can add to the challenge is that many of these companies are small-cap companies that are not well-known names.
These small biotech stocks may shoot higher based on a vaccine or drug candidate that gets national attention. But these small-cap stock also reflect the adage of letting the buyer beware. Because the stark reality for many investors is that the vast majority of these treatments never make it past clinical trials. And that means that a stock that goes up rapidly can move down just as fast.
We’re seeing that right now with the multitude of companies that are competing in the race towards a vaccine and/or treatment for Covid-19 and the novel coronavirus that causes the disease. And if you’ve been good at timing the market, you could have made some good money on some of these candidates.
Of course, if you held the stock too long, you could have lost your shirt as well.
That doesn’t mean however that buy and hold investors should avoid the biotech sector altogether. There are still some attractively priced small-cap biotech companies that are working on treatments for a range of conditions that provide them with a large addressable base. And we’ve identified seven of these stocks in this special presentation.
View the "7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure".